Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

NCT05189093 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Lymphoma

Interventions

DRUG: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection

Sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd.